Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary
- Creators
- Abu-Shama, Yazan
- Salleron, Julia
- Carsuzaa, Florent
- Sun, Xu-Shan
- Pflumio, Carole
- Troussier, Idriss
- Petit, Claire
- Caubet, Matthieu
- Beddok, Arnaud
- Calugaru, Valentin
- Servagi-Vernat, Stephanie
- Castelli, Joël
- Miroir, Jessica
- Krengli, Marco
- Giraud, Paul
- Romano, Edouard
- Khalifa, Jonathan
- Doré, Mélanie
- Blanchard, Nicolas
- Coutte, Alexandre
- Dupin, Charles
- Sumodhee, Shakeel
- Tao, Yungan
- Roth, Vincent
- Geoffrois, Lionel
- Toussaint, Bruno
- Nguyen, Duc
- Faivre, Jean-Christophe
- Thariat, Juliette
- Others:
- Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
- Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL) ; UNICANCER
- Centre hospitalier universitaire de Poitiers (CHU Poitiers)
- Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Centre Hospitalier Universitaire de Nice (CHU Nice)
- Institut Gustave Roussy (IGR)
- Département de radiothérapie [Gustave Roussy] ; Institut Gustave Roussy (IGR)
- Institut Curie [Paris]
- Institut Jean Godinot [Reims] ; UNICANCER
- Centre Eugène Marquis (CRLCC)
- Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP) ; UNICANCER
- Università degli Studi del Piemonte Orientale - Amedeo Avogadro (UPO)
- Service d'oncologie-radiothérapie [CHU Tenon] ; CHU Tenon [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037) ; Université Toulouse III - Paul Sabatier (UT3) ; Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO) ; UNICANCER
- Clinique des Dentellières [Valenciennes, France]
- CHU Amiens-Picardie
- CHU Bordeaux [Bordeaux]
- Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UCA)
- Easy Global Market [Sophia-Antipolis]
- Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC) ; Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)
Description
Simple Summary: A retrospective multicentric study of 322 patients with head and neck cancers of unknown primary (HNCUP) was performed testing the impact of neck dissection (ND) extent on nodal relapse, progression-free survival and survival. After 5 years, the incidence of nodal relapse was 13.4%, and progression-free survival (PFS) was 59.1%. In multivariate analysis after adjusting for nodal stage, the risk of nodal relapse or progression was reduced with lymphadenectomy, selective ND or radical/modified ND but survival rates were similar. Patients undergoing lymphadenectomy or ND had significantly better PFS and a lower nodal relapse incidence in the N1 + N2a group, but the improvement was not significant for the N2b or N2 + N3c patients. Severe toxicity rates exceeded 40% with radical ND. In HNCUP, ND improves PFS regardless of nodal stage but fails to improve survival. The magnitude of the benefit of ND did not appear to depend on ND extent and decreased with a more advanced nodal stage.Abstract: Purpose: Management of head and neck cancers of unknown primary (HNCUP) combines neck dissection (ND) and radiotherapy, with or without chemotherapy. The prognostic value of ND has hardly been studied in HNCUP.Methods: A retrospective multicentric study assessed the impact of ND extent (adenectomy, selective ND, radical/radical-modified ND) on nodal relapse, progression-free survival (PFS) or survival, taking into account nodal stage. Results: 53 patients (16.5%) had no ND, 33 (10.2%) had lymphadenectomy, 116 (36.0%) underwent selective ND and 120 underwent radical/radical-modified ND (37.3%), 15 of which received radical ND (4.7%). With a 34-month median follow-up, the 3-year incidence of nodal relapse was 12.5% and progression-free survival (PFS) 69.1%. In multivariate analysis after adjusting for nodal stage, the risk of nodal relapse or progression was reduced with lymphadenectomy, selective or radical/modified ND, but survival rates were similar. Patients undergoing lymphadenectomy or ND had a better PFS and lowered nodal relapse incidence in the N1 + N2a group, but the improvement was not significant for the N2b or N2 + N3c patients. Severe toxicity rates exceeded 40% with radical ND. Conclusion: In HNCUP, ND improves PFS, regardless of nodal stage. The magnitude of the benefit of ND does not appear to depend on ND extent and decreases with a more advanced nodal stage
Abstract
International audience
Additional details
- URL
- https://hal.sorbonne-universite.fr/hal-03244833
- URN
- urn:oai:HAL:hal-03244833v1
- Origin repository
- UNICA